Experience

• Ms. Dotolo has represented either the issuer or the underwriters in numerous IPOs, follow-on offerings and other equity and debt offerings, including the following:

  • Inozyme Pharma in its $128.8 million initial public offering, $73.1 million follow-on offering and $69 million follow-on offering
  • Curis in its $15.1 million registered direct offering
  • Disc Medicine in its $157.8 million follow-on public offering
  • Solid Biosciences in its numerous private placements, including, most recently, a $109 million private placement
  • Cue Biopharma in its $30 million private placement 
  • Syros Pharmaceuticals in its $130 million and $11.3 million private placements
  • Fulcrum Therapeutics in its $72 million initial public offering, $68.5 million private placement, $50.6 million follow-on offering and $144.2 million follow-on offering
  • Arvinas in its $459.9 million follow-on offering and $350 million private placement
  • Editas in its $215.6 million follow-on offering
  • A clinical-stage pharmaceutical company in its $52 million private placement
  • Altiostar Networks in numerous venture financings
  • Trevi Therapeutics in its $55 million initial public offering
  • Constellation Pharmaceuticals in its $60 million initial public offering
  • Flywire in numerous venture financings
  • Idera Pharmaceuticals in its $52.5 million, $57.5 million, $40 million, $27.7 million and $16.5 million follow-on offerings
  • Spark Therapeutics in its $402.5 million follow-on offering
  • An American investment management firm in its public offering of $300 million in senior notes
  • Merrimack Pharmaceuticals in its 144A offering of $175 million in senior notes
  • Bellerophon Therapeutics in its $60 million initial public offering